Philippe Aftimos, MD
@aftimosp.bsky.social
Breast oncologist and clinical researcher 🩺🔬at Institut Jules bordet 🏥. Dad of a 5-yo 🧑🧒 and of a cat 🐈. Nature lover 🌳, oud enthusiast 🎼, vegan 🌱, RUSG fan ⚽️💛💙. Proud citizen of Wokistan.
Rotterdam citytrip and Union Saint-Gilloise 💛💙 at De Kuip
🚂☀️🚤🏟️
🚂☀️🚤🏟️
July 12, 2025 at 5:40 PM
Rotterdam citytrip and Union Saint-Gilloise 💛💙 at De Kuip
🚂☀️🚤🏟️
🚂☀️🚤🏟️
I am a big fan of @fontainesdc.bsky.social and I discovered their partnership with @bfcdublin.bsky.social at Rock Werchter. I immediately loved the club’s vibes. And that third jersey, wow 🤩
July 8, 2025 at 7:11 PM
I am a big fan of @fontainesdc.bsky.social and I discovered their partnership with @bfcdublin.bsky.social at Rock Werchter. I immediately loved the club’s vibes. And that third jersey, wow 🤩
July 3, 2025 at 3:30 PM
I reviewed for @myesmo.bsky.social new data with a potential clinical impact in HR+/HER2- metastatic breast cancer 👇
Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations.
Read the opinion by @aftimosp.bsky.social in the #ESMODailyReporter
🔗 buff.ly/QGEixeU
#MBC #BreastCancer #ctDNA
Read the opinion by @aftimosp.bsky.social in the #ESMODailyReporter
🔗 buff.ly/QGEixeU
#MBC #BreastCancer #ctDNA
June 16, 2025 at 7:49 AM
I reviewed for @myesmo.bsky.social new data with a potential clinical impact in HR+/HER2- metastatic breast cancer 👇
Reposted by Philippe Aftimos, MD
#ESMOMembers – vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee.
📽️ Watch the ESMO President’s message
🔗 Vote now: ow.ly/H7UK50VZR0X
📽️ Watch the ESMO President’s message
🔗 Vote now: ow.ly/H7UK50VZR0X
May 28, 2025 at 8:21 AM
#ESMOMembers – vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee.
📽️ Watch the ESMO President’s message
🔗 Vote now: ow.ly/H7UK50VZR0X
📽️ Watch the ESMO President’s message
🔗 Vote now: ow.ly/H7UK50VZR0X
Cool simultaneous illustration of my talk at the seminar series organised by Institut Jules Bordet to celebrate Clinical Trials Day
May 24, 2025 at 12:11 PM
Cool simultaneous illustration of my talk at the seminar series organised by Institut Jules Bordet to celebrate Clinical Trials Day
🇩🇪 🚆 🇧🇪 🚌 🏟️ ⚽️💛💙
May 17, 2025 at 6:56 AM
🇩🇪 🚆 🇧🇪 🚌 🏟️ ⚽️💛💙
Reposted by Philippe Aftimos, MD
@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins
May 16, 2025 at 7:11 AM
@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins
Day 2 of #ESMOBreast25 in Munich.
Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC:
emiltatug ledadotin and puxitatug samrotecan
#ESMOAmbassadors @myesmo.bsky.social
Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC:
emiltatug ledadotin and puxitatug samrotecan
#ESMOAmbassadors @myesmo.bsky.social
May 15, 2025 at 6:12 AM
Day 2 of #ESMOBreast25 in Munich.
Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC:
emiltatug ledadotin and puxitatug samrotecan
#ESMOAmbassadors @myesmo.bsky.social
Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC:
emiltatug ledadotin and puxitatug samrotecan
#ESMOAmbassadors @myesmo.bsky.social
May 14, 2025 at 7:48 PM
Reposted by Philippe Aftimos, MD
In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.
Full article in the #ESMODailyReporter
🔗 ow.ly/rtbo50VSyiN
Full article in the #ESMODailyReporter
🔗 ow.ly/rtbo50VSyiN
May 14, 2025 at 1:41 PM
In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.
Full article in the #ESMODailyReporter
🔗 ow.ly/rtbo50VSyiN
Full article in the #ESMODailyReporter
🔗 ow.ly/rtbo50VSyiN
Reposted by Philippe Aftimos, MD
#ESMOBreast25 Award recipient, Gabriel Hortobagyi, describes the long journey that has led to targeted #BreastCancer therapies and explains how patient involvement is central to advancing research.
Read more in the #ESMODailyReporter
🔗 ow.ly/kqju50VSpOE
Read more in the #ESMODailyReporter
🔗 ow.ly/kqju50VSpOE
May 14, 2025 at 11:36 AM
#ESMOBreast25 Award recipient, Gabriel Hortobagyi, describes the long journey that has led to targeted #BreastCancer therapies and explains how patient involvement is central to advancing research.
Read more in the #ESMODailyReporter
🔗 ow.ly/kqju50VSpOE
Read more in the #ESMODailyReporter
🔗 ow.ly/kqju50VSpOE
Reposted by Philippe Aftimos, MD
At #ESMOBreast25, refinements in #LiquidBiopsy use are reviewed, including a defined window for ESR1 mutation detection in metastatic #BreastCancer and use of pre-neoadjuvant treatment #ctDNA levels to predict recurrence.
More in the #ESMODailyReporter
🔗 ow.ly/R93050VSChg
More in the #ESMODailyReporter
🔗 ow.ly/R93050VSChg
May 14, 2025 at 2:37 PM
At #ESMOBreast25, refinements in #LiquidBiopsy use are reviewed, including a defined window for ESR1 mutation detection in metastatic #BreastCancer and use of pre-neoadjuvant treatment #ctDNA levels to predict recurrence.
More in the #ESMODailyReporter
🔗 ow.ly/R93050VSChg
More in the #ESMODailyReporter
🔗 ow.ly/R93050VSChg
An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
May 14, 2025 at 1:06 PM
An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social
May 14, 2025 at 12:25 PM
#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social
May 13, 2025 at 3:01 PM
Reposted by Philippe Aftimos, MD
Reposted by Philippe Aftimos, MD
#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf
🔗 ow.ly/VtAE50VP4Jf
May 12, 2025 at 7:32 AM
#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf
🔗 ow.ly/VtAE50VP4Jf
May 4, 2025 at 7:43 PM
May 1, 2025 at 2:11 PM
Reposted by Philippe Aftimos, MD
🚀 ESMO is now on Bluesky
This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.
Join us for the latest in oncology education and information.
#AIOncology #HealthAI #ESMOAI25
This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.
Join us for the latest in oncology education and information.
#AIOncology #HealthAI #ESMOAI25
April 1, 2025 at 7:36 AM
🚀 ESMO is now on Bluesky
This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.
Join us for the latest in oncology education and information.
#AIOncology #HealthAI #ESMOAI25
This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.
Join us for the latest in oncology education and information.
#AIOncology #HealthAI #ESMOAI25
Reposted by Philippe Aftimos, MD
Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice.
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: ow.ly/uQGA50Vvu4j
@benwestphalen.bsky.social
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: ow.ly/uQGA50Vvu4j
@benwestphalen.bsky.social
April 7, 2025 at 8:03 AM
Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice.
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: ow.ly/uQGA50Vvu4j
@benwestphalen.bsky.social
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: ow.ly/uQGA50Vvu4j
@benwestphalen.bsky.social
Reposted by Philippe Aftimos, MD
📣#ESMOBreast25: Regular abstract titles and authors are online! Check the programme to see the exciting studies you will have the chance to see at this event.
⏰And if you register by 17 April, you can benefit from advantageous rates!
🔗 buff.ly/9Ply77K
⏰And if you register by 17 April, you can benefit from advantageous rates!
🔗 buff.ly/9Ply77K
April 10, 2025 at 1:27 PM
📣#ESMOBreast25: Regular abstract titles and authors are online! Check the programme to see the exciting studies you will have the chance to see at this event.
⏰And if you register by 17 April, you can benefit from advantageous rates!
🔗 buff.ly/9Ply77K
⏰And if you register by 17 April, you can benefit from advantageous rates!
🔗 buff.ly/9Ply77K
So many interesting discussions with very bright 💡 people!
The #AURORA Data Analysis Committee is in Florence for a “datathon”! Over the next 2 days, PIs, bioinformaticians, clinicians, and BIG HQ are working together on analyses to advance a new AURORA manuscript. @aftimosp.bsky.social
@elisaagostinetto.bsky.social
@elisaagostinetto.bsky.social
April 10, 2025 at 11:27 AM
So many interesting discussions with very bright 💡 people!